China's Fosun Pharma has divested a 6% stake in Hyderabad-based Gland Pharma for approximately ₹2,800 crore through a block deal. This significant transaction reduces Fosun's holding to 45.77% and signals potential strategic shifts for both companies.
6%
Stake Sold
⏳ Time Machine
How today’s news fits into the bigger picture
2017
Fosun Acquires Majority Stake
Fosun Pharma acquired a majority stake (around 74%) in Gland Pharma for approximately $1.1 billion, marking a significant entry of Chinese capital into India's .
2020
Gland Pharma IPO Launches
Gland Pharma successfully launched its Initial Public Offering (IPO), raising ₹6,480 crore, becoming the first major Indian pharmaceutical company with Chinese ownership to list on Indian bourses.
2020-2022
Scrutiny on Chinese Investments
Amidst geopolitical tensions, India increased regulatory scrutiny on Chinese investments, leading to reviews and stricter approval processes for proposals involving Chinese entities in various sectors, including pharma.
Early 2026
Strong Q1 Performance Reported
Gland Pharma reported robust first-quarter results, driven by strong demand for its injectables and expanded market presence in regulated markets, signaling operational strength despite external factors.
August 2026
Mutual Funds Boost Pharma Exposure
Several Indian mutual funds significantly increased their exposure to the , seeking defensive plays and stable returns amidst global economic uncertainties, creating strong domestic buying interest for quality pharma stocks.
Today
China's Fosun Pharma divested a 6% stake in Gland Pharma for ₹2,800 crore through a block deal, reducing its holding to 45.77%.
What happens next?
The increased institutional ownership could lead to greater market scrutiny and potentially influence Gland Pharma's future strategic decisions, while investors watch for further stake adjustments by Fosun.
China-based Fosun Pharma has reduced its ownership in Indian pharmaceutical company Gland Pharma, selling a **6% stake** for approximately **₹2,800 crore** via a block deal. This transaction lowers Fosun Pharma's holding in Gland Pharma to **45.77%**. The buyers primarily included major institutional investors such as Kotak, Axis, and ICICI Prudential Mutual Funds. This strategic divestment by Fosun Pharma could be driven by a re-evaluation of its global portfolio, a need to unlock capital, or a response to the evolving regulatory and geopolitical landscape affecting Chinese investments in India. For Gland Pharma, this could lead to increased institutional investor interest and a more diversified ownership structure.
💭 If you're wondering…
A block deal is a large, single transaction of shares, typically between institutional investors. It's usually executed through a separate trading window to prevent the large volume from significantly impacting the stock's price in regular market trading.
Did this story help?
Official sources
Knowledge Chain — tap a concept